High-dose omega-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: a network meta-analysis
| Autor: | Qiao-ting Huang, Bo Yang, Kuan-Pin Su, Jin-shan Feng, Ju-da Lin, Ji-yang Pan, Zheng Yang, Xu-dong Luo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty lcsh:RC435-571 Supplementation Network Meta-Analysis Major depressive disorder Cochrane Library Placebo law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law lcsh:Psychiatry Internal medicine Fatty Acids Omega-3 medicine Adjuvant therapy Humans 030212 general & internal medicine Omega-3 Depressive Disorder Major Dose-Response Relationship Drug business.industry medicine.disease Comorbidity Clinical trial Psychiatry and Mental health Treatment Outcome Polyunsaturated fatty acid Meta-analysis Dietary Supplements Fatty Acids Unsaturated business 030217 neurology & neurosurgery Research Article |
| Zdroj: | BMC Psychiatry BMC Psychiatry, Vol 20, Iss 1, Pp 1-8 (2020) |
| ISSN: | 1471-244X |
| Popis: | Background The application of n-3 Polyunsaturated Fatty Acids (n-3 PUFAs) supplementation for major depressive disorder (MDD) has been widely discussed in recent years, but its efficacy and application are still controversial. This network meta-analysis was conducted to compare the efficacy of different dosages of n-3 PUFAs on MDD patients in the early period of treatment. Methods Randomized controlled trials (RCTs) exploring the efficacy of n-3 PUFA supplementation for patients with MDD were retrieved from the databases of Pubmed, Embase and the Cochrane Library. RCTs comparing the efficacy of n-3 PUFA for adult (≥18 years) MDD patients without comorbidity were eligible for our study. The score of depressive symptoms in early therapy period of the treatment (≤9 weeks) was extracted. Standardized mean deviations (SMDs) of all the sores from the eligible RCTs were synthesized in a pairwise meta-analysis in frequentist framework and a random-effects network meta-analysis in Bayesian framework for the overall and subgroups (high- and low-dose) efficacy of n-3 PUFAs. Results A total of 910 MDD patients in 10 trials with 3 adjuvant therapy strategies (high-dose n-3 PUFAs, low-dose n-3 PUFAs and placebo) were included. Results of pairwise meta-analysis showed that n-3 PUFAs were superior to placebo (SMD: 1.243 ± 0.596; 95% CI: 0.060 ~ 2.414). Results of the network meta-analysis showed that both the high (SMD: 0.908 ± 0.331; 95% CI: 0.262 ~ 1.581) and the low-dose (SMD: 0.601 ± 0.286; 95% CI: 0.034 ~ 1.18) n-3 PUFAs were superior to placebo, and the efficacy of high-dose n-3 PUFAs is superior to that of low-dose. Conclusions High-dose n-3 PUFAs supplementation might be more superior than low-dose in the early therapy period for MDD. More head-to-head clinical trials need to be carried out to provide more direct comparison and enhance the evidence of the efficacy of n-3PUFAs for MDD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink